PMVP vs RAIN vs OESX vs KYMR

For growth investors, Orion Energy Systems, Inc.

(OESX) is the stronger pick with -12. 0% revenue growth year-over-year, versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). Analysts rate Kymera Therapeutics, Inc. (KYMR) a "Buy" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Kymera Therapeutics, Inc.

(KYMR) delivered a total return of +92. 1%, compared to -95. 9% for PMV Pharmaceuticals, Inc. (PMVP). Over 10 years, the gap is even starker: KYMR returned +154. 4% versus PMVP's -96. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), PMV Pharmaceuticals, Inc.

(PMVP) is the lower-risk stock at 0. 76β versus Rain Enhancement Technologies Holdco Inc's 1. 20β — meaning RAIN is approximately 58% more volatile than PMVP relative to the S&P 500. On balance sheet safety, PMV Pharmaceuticals, Inc. (PMVP) carries a lower debt/equity ratio of 1% versus 87% for Orion Energy Systems, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Orion Energy Systems, Inc.

(OESX) is pulling ahead at -12. 0% versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). On earnings-per-share growth, the picture is similar: PMV Pharmaceuticals, Inc. grew EPS 21. 0% year-over-year, compared to -34. 9% for Rain Enhancement Technologies Holdco Inc. Over a 3-year CAGR, KYMR leads at -5. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

PMV Pharmaceuticals, Inc.

(PMVP) is the more profitable company, earning 0. 0% net margin versus -794. 4% for Kymera Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PMVP leads at 0. 0% versus -891. 3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, PMV Pharmaceuticals, Inc.

(PMVP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 76)). Both have compounded well over 10 years (PMVP: -96. 2%, RAIN: -80. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (PMVP (Healthcare) and RAIN (Utilities) and OESX (Industrials) and KYMR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.